Viridian Therapeutics, Inc./DE (VRDN)

Import this data to Google Sheets with:

=jivedata("VRDN","financials")

Full statements spill as a table. For one cell: =jivedata("VRDN","Revenue") or =jivedata("VRDN","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Viridian Therapeutics, Inc./DE

VRDN • CIK 0001590750

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-254,450	$-299,035	$-363,395	$-405,199
Net Income (Loss) Attributable to Parent	$-237,734	$-269,949	$-342,601	$-386,974
Weighted Average Number of Shares Outstanding, Basic	44,755,475	—	—	65,498,615
Revenue from Contract with Customer, Including Assessed Tax	$314	$302	$70,849	$71,127
Research and Development Expense (Excluding Acquired in Process Cost)	$159,765	$238,254	$338,929	$324,676
Selling, General and Administrative Expense	—	—	$95,315	$151,650
Operating Expenses	$254,764	$299,337	$434,244	$476,326
Investment Income, Interest	—	—	$27,399	$29,675
InterestExpenseNonoperating	—	$3,046	$4,948	$15,617
Other Operating Income (Expense), Net	—	—	$-1,657	$-2,173
Nonoperating Income (Expense)	$16,716	$29,086	$20,794	$18,225
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-237,006	$-270,297	$-342,144	$-388,196
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	—	—	$457	$-1,228
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$728	$-348	$457	$-1,222

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Net	$1,672	$1,236	$1,228	$2,765
Operating Lease, Right-of-Use Asset	$1,670	$2,205	$2,421	$2,085
Other Assets, Noncurrent	$604	$501	$1,536	$1,113
Assets	$490,424	$742,403	$899,418	$1,097,233
Secured Long-term Debt, Noncurrent	—	—	$49,940	$0
Derivative Liability, Noncurrent	—	—	$20,030	$13,690
Other Long-term Debt, Noncurrent	—	—	$34,244	$113,642
Other Liabilities, Noncurrent	$989	$2,024	$2,341	$1,851
Liabilities	$48,402	$70,764	$177,251	$435,136
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$102,827	$99,594	$212,382	$164,986
Debt Securities, Available-for-sale, Current	$374,543	$617,990	$662,270	$816,544
Prepaid Expense and Other Assets, Current	$9,006	$20,877	$19,581	$24,740
Assets, Current	$486,478	$738,461	$894,233	$1,081,270
Accounts Payable, Current	$2,239	$2,143	$8,683	$8,652
Accrued Liabilities, Current	$24,108	$45,443	$62,013	$55,142
Liabilities, Current	$26,635	$47,874	$70,696	$63,794
Common Stock, Value, Issued	$540	$810	$1,018	$1,132
Additional Paid in Capital	$960,536	$1,477,811	$1,927,104	$2,134,572
Accumulated Other Comprehensive Income (Loss), Net of Tax	$338	$-10	$447	$-1,153
Retained Earnings (Accumulated Deficit)	$-725,908	$-995,857	$-1,338,458	$-1,570,478
Stockholders' Equity Attributable to Parent	$442,022	$671,639	$722,167	$662,097
Preferred Stock, Shares Authorized	5,000,000	5,000,000	5,000,000	5,000,000
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	53,986,112	80,994,046	101,826,500	113,238,218

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-52,752	$-3,233	$112,788	$47,662
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$102,827	$99,594	$212,382	$272,513
Net Income (Loss) Attributable to Parent	$-237,734	$-269,949	$-342,601	$-386,974
Net Cash Provided by (Used in) Operating Activities	$-184,170	$-232,319	$-276,391	$-333,343
Payments to Acquire Debt Securities, Available-for-sale	$407,880	$695,068	$579,276	$922,253
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	$314,526	$466,928	$542,208	$556,710
Payments to Acquire Property, Plant, and Equipment	$898	$511	$495	$1,696
Net Cash Provided by (Used in) Investing Activities	$-94,252	$-228,651	$-37,563	$-367,239
Proceeds from Issuance Initial Public Offering	—	—	$289,052	$289,052
Proceeds from Issuance of Common Stock	$125,069	$453,660	$63,145	$58,201
Proceeds from Issuance of Convertible Preferred Stock	$0	$25,001	$0	$0
Proceeds from Issuance of Warrants	—	$0	$1,618	$0
Proceeds from Issuance of Long-term Debt	—	$0	$28,875	$28,875
Payments of Debt Issuance Costs	$0	$0	$478	$7,984
Proceeds from Issuance of Debt	—	—	$55,000	$55,000
Proceeds from Stock Options Exercised	$19,263	$5,344	$12,053	$15,927
Proceeds from Stock Plans	$580	$674	$1,119	$1,828
Net Cash Provided by (Used in) Financing Activities	$225,670	$457,737	$426,742	$748,244
Interest Paid, Excluding Capitalized Interest, Operating Activities	$886	$1,820	$2,150	$3,472
Conversion of Stock, Amount Issued	—	—	$56,829	$90,861
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	—	$496	$729	$729
Notes Reduction	$4,707	$0	$20,000	$20,000
Notes Issued	$5,000	$0	$20,000	$20,000
Share-based Payment Arrangement, Noncash Expense	$67,172	$42,150	$44,303	$53,613
Accretion (Amortization) of Discounts and Premiums, Investments	$11,490	$15,655	$6,758	$6,194
Paid-in-Kind Interest	—	—	$2,566	$7,242
Depreciation, Depletion and Amortization	$522	$540	$460	$468
Derivative, Gain (Loss) on Derivative, Net	—	—	$-700	$5,640
Issuance of Stock and Warrants for Services or Claims	$5,693	$0	$0	$0
Other Noncash Income (Expense)	$-31	$0	$-157	$-332
Increase (Decrease) in Prepaid Expense and Other Assets	$2,107	$11,768	$-262	$9,953
Increase (Decrease) in Accounts Payable	$-12,040	$-73	$6,562	$-408
Increase (Decrease) in Accrued Liabilities	$5,010	$21,625	$16,207	$8,355

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("VRDN","financials")

Full statements spill as a table. For one cell: =jivedata("VRDN","Revenue") or =jivedata("VRDN","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.